Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A double-blind, randomized, placebo-and active-controlled efficacy and safety study of bazedoxifene/conjugated estrogens combinations for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women

Trial Profile

A double-blind, randomized, placebo-and active-controlled efficacy and safety study of bazedoxifene/conjugated estrogens combinations for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 Nov 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Conjugated estrogens/bazedoxifene (Primary) ; Bazedoxifene
  • Indications Atrophic vaginitis; Female sexual dysfunction
  • Focus Registrational; Therapeutic Use
  • Acronyms SMART-3
  • Sponsors Wyeth
  • Most Recent Events

    • 08 Oct 2016 Pooled post hoc analysis results of SMART-1 (NCT00675688), SMART-2 (NCT00234819), SMART-3 (NCT00238732), SMART-4 (NCT00242710), and SMART-5 (NCT00808132) presented at the 27th North American Menopause Society
    • 09 Feb 2015 According to a Ligand Pharmaceuticals media release, Pfizer received EU marketing approval for DUAVIVE based on the data from this study.
    • 12 Oct 2013 Pooled tolerability results presented at the 24th Annual Meeting of the North American Menopause Society.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top